Skip to main content

Table 2 Pathology and survival information

From: Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases

Number Grade Stage T N M EGFR IHC EGFR mutation Recurrence metastasis Survival status OS/month/month PFS/month/month
1 Low Ia 1a 0 0 50%++ N/A - Alive 29 29
2 Low Ia 1a 0 0 0 - - Alive 76 76
3 Low Ia 1a 0 0 0 - - Alive 77 77
4 Low Ia 1b 0 0 0 - - Alive 62 62
5 Low Ia 1b 0 0 0 - - Alive 5 5
6 Low Ib 2a 0 0 30%+ - - Alive 22 22
7 Low Ib 2a 0 0 0 - - Alive 46 46
8 Low Ib 2a 0 0 0 - Recurrence Dead 41 40
9 Low Ib 2a 0 0 90%+ - - Alive 66 66
10 Low Ib 2a 0 0 0 - - Alive 67 67
11 Low Ib 2a 0 0 0 - - Alive 67 67
12 Low IIa 2a 1 0 20%+ - - Alive 29 29
13 Low IIb 3 0 0 0 - - Alive 5 5
14 Low IIb 3 0 0 0 - - Alive 54 54
15 Low IIIb 4 2 0 90%++ - - Perioperative dead - -
16 Low - 3 x 0 0 N/A - Alive 74 74
17 Low - 1b x 0 0 - - Alive 25 25
18 High Ia 1a 0 0 0 - - Alive 47 47
19 High IIb 2b 1 0 100%+ - Contralateral lung metastasis Dead 65 63
20 High IIIa 2a 2 0 0 - Recurrence Dead 31 30
21 High IIIa 2a 2 0 0 - Liver metastasis Dead 23 15
  1. EGFR epidermal growth factor receptor, IHC immunohistochemistry, N/A not available, OS overall survival, PFS Progression-free survival, TNM tumor-node-metastasis.